Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein

Cancer Control

Volumn 10, Issue 2, 2003, Pages 159-165

  Thomas, Hilary ^a   Coley, Helen M ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BIRICODAR; BISANTRENE; CALMODULIN INHIBITOR; CYCLOSPORIN A; CYCLOSPORIN D; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DEXNIGULDIPINE; DEXVERAPAMIL; DOCETAXEL; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; LANIQUIDAR; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ONT 093; PACLITAXEL; TAMOXIFEN; TARIQUIDAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; ZOSUQUIDAR;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TRANSPORT; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; TOXICITY;

EID: 0037358040     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480301000207     Document Type: Review

References (54)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
2. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-398.
3. Fardel O, Lecureur V. Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol. 1996;27:1283-1291.
4. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265-283.
5. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427.
6. Witherspoon SM, Emerson DL, Kerr BM, et al. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res. 1996;2:7-12.
7. Cayre A, Cachin F, Maublant J, et al. Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. Int J Oncol. 2002;20:1049-1055.
8. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156-1166.
9. Abolhoda A, Wilson AE, Ross H, et al. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 1999;5:3352-3356.
10. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer. 1996;32A:1070-1081.
11. Chan HS, Thorner PS, Haddad G, Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990;8:689-704.
12. Chan HS, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991;325:1608-1614.
13. Chan HS, DeBoer G, Thiessen JJ. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1996;2:1499-1508.
14. Theis JG, Chan HS, Greenberg ML, et al. Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. Med Pediatr Oncol. 2000;34:242-249.
15. te Boekhorst PA, van Kapel J, Schoester M, et al. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmacol. 1992;30:238-242.
16. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer. 1991;27:1639-1642.
17. Advani R, Fisher GA, Lum BL, et al. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res. 2001;7:1221-1229.
18. Baekelandt M, Lehne G, Trope CG, et al. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol. 2001;19:2983-2993.
19. Fracasso PM, Brady MF, Moore DH, et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001;19:2975-2982.
20. Advani R, Saba HI, Tallman MS, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 1999;93:787-795.
21. Dorr R, Karanes C, Spier C, et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol. 2001;19:1589-1599.
22. Fracasso PM, Westervelt P, Fears CL, et al. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol. 2000;18:1124-1134.
23. Bates S, Kang M, Meadows B, et al. A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer. 2001;92:1577-1590.
24. Chauncey TR, Rankin C, Anderson JE, et al. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. Leuk Res. 2000;24:567-574.
25. Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res. 1997;3:2005-2015.
26. Boote DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol. 1996;14:610-618.
27. Coley HM, Verrill MW, Gregson SE. Incidence of P-glycoprotein over expression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur J Cancer. 2000;36:881-888.
28. Coley HM, Sargent JM, Williamson CJ, et al. Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study. Anticancer Res. 2002;22:69-74.
29. Germann UA, Shlyakhter D, Mason VS, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 1997;8:125-140.
30. Germann UA, Ford PJ, Shlyakhter D, et al. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP Anticancer Drugs. 1997;8:141-155.
31. Yanagisawa T, Newman A, Coley H, et al. BIRICODAR(VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer. 1999;80:1190-1196.
32. Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol. 2001;19:832-842.
33. Lum BL, Gosland MP. MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am. 1995;9:319-336.
34. Wandel C, Kim RB, Kajiji S, et al. P-Glycoprotein and cytochrome P450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res. 1999;59:3944-3948.
35. Fischer V, Rodriguez-Gascon A, Heitz F, et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P-450 3A: implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos. 1998;26:802-811.
36. Rowinsky EK, Smith L, Wang YM, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998;16:2964-2976.
37. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells. 2002;20:11-20.
38. Dantzig AH, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P- glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999;290:854-862.
39. Mistry P, Stewart Al, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001;61:749-758.
40. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996;56:4171-4179.
41. Roe M, Folkes A, Ashworth P, et al. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett. 1999;9:595-600.
42. Starling JJ, Shepard RL, Cao J, et al. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul. 1997;37:335-347.
43. van Zuylen L, Nooter K, Sparreboom A, et al. Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs. 2000;18:205-220.
44. Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of P- glycoprotein-mediated multidrug resistance. Cancer Res. 2000;60:2964-2972.
45. Maliepaard M, van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)- mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res. 2001;7:935-941.
46. Martin C, Berridge G, Mistry P, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999;128:403-411.
47. Stewart A, Steiner J, Mellows G, et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res. 2000;6:4186-4191.
48. Abraham J, Edgerly M, Wilson R, et al. A phase I study of the novel P-glycoprotein (Pgp) antagonist, XR9576 in combination with vinorelbine. Proc Annu Meet Am Soc Clin Oncol. 2001;20:287. Abstract.
49. Thomas H, Steiner JA, Mould GP, et al. A phase IIa pharmacokinetic study of the P-glycoprotein inhibitor, XR9576, in combination with paditaxel in patients with ovarian cancer. Proc Annu Meet Am Soc Clin Oncol. 2001;20:288. Abstract.
50. Ferry D, Price L, Atsmon J, et al. A phase IIa pharmacokinetic and pharmacodynamic study of the P-glycoprotein inhibitor, XR9576 in patients treated with doxorubicin chemotherapy. Proc Annu Meet Am Assoc Cancer Res. 2001;42:950. Abstract 5106.
51. Cripe LD, Tallman M, Karanes C. A phase II trial of zosuquidar (LY335979), a modulator of P-glycoprotein (P-gp) activity, plus daunorubicin and high-dose cytarabine in patients with newly-diagnosed secondary acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-t), or relapsed/refractory AML. Blood. 2001;98:595a. Abstract.
52. Tura S, Morschhauser F, Zinzani P, et al. A phase I trial of the P-glycoprotein (Pgp) inhibitor zosuquidar (LY335979) and CHOP chemotherapy in patients with non-Hodgkin's lymphoma. Blood. 2001;98:251b. Abstract.
53. Shepard RL, Cao J, Starling JJ, et al. Modulation of P-glycoprotein but not MRP-1-or BCRP-mediated drug resistance by LY335979. Int J Cancer. 2003;103:121-125.
54. Dantzig AH, Tabas LB, Law KL et al. In vitro characterization of selective and highly potent tricyclic isoxazole inhibitors of the multidrug resistant protein MRP1. Proc Annu Meet Am Assoc Cancer Res. 2002;43:951. Abstract.